As an example of TAAs, melanocyte differentiation proteins (e.g., gp100, tyrosinase) [10] and Human epidermal growth factor receptor 2 (HER2) [11], as well as Cancer-testis antigens, including New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and the melanoma antigen gene (MAGE) protein family [12], have been used as cancer vaccines in many clinical trials to elicit responses against multiple class I and class II MHC-restricted epitopes. This evidence concerns the gene TYR and cancer.